INTRODUCTION
Preexposure prophylaxis (PrEP) for HIV is the use of drugs, typically antiretrovirals, by uninfected individuals to prevent them from acquiring HIV infection. Currently Truvada is the only Food and Drug Administration (FDA)-approved medicine and the USA has been the only country where this preventive strategy has been approved, although there are active regulatory submissions in other countries. We discuss the uptake of and issues for implementation in the USA with extensive documentation of the challenges of integrating this approach into the US healthcare system from the provider and community perspectives.
, 7] . Based on these findings, the Centers for Disease Control and Prevention (CDC), World Health Organization, and International AIDS Society USA issued guidance on the use of tenofovir and Truvada for HIV prevention, and recommended PrEP use as part of prevention strategies in multiple high-risk populations [8] [9] [10] .
The utilization of PrEP has been sluggish in the USA since the FDA ruling in 2012. Gilead's analysis of 55% of all retail US pharmacies demonstrated approximately 8512 individuals utilizing this strategy from 2012-2013 to 2015, with an increasing pace of growth over the last 12 months (Gilead communication). It is difficult to estimate the size of the population that would be appropriate for PrEP, but clearly the current usage patterns are only reaching a minority of those who might benefit. Grant estimated that 11.2% of MSM in San Francisco in 2014 were currently on PrEP and approximately 32% had ever tried PrEP [11] .
Estimates of the pool of individuals appropriate for PrEP include all sexually active individuals who meet the CDC-defined definition of risk. Lieb and colleagues [12] estimate that overall MSM rates in the USA were 7.4% of the total population equating to 7.4 million men in this at risk population alone. Current estimates are that 65% of new HIV infections are attributed to MSM contact [13] . The CDC has estimated that 6.9% of men have had sexual contact with other men and approximately 3% in the last 12 months [14] equating to a potential pool of approximately 200,000 MSM who may qualify for PrEP, depending on their unprotected encounters in the last 6 months.
The current utilization of approximately 9000 is modest compared to the size of the potential of MSM, and heterosexual men and women with behaviors that are considered high risk according to the CDC. There are approximately 50 000 new HIV infections yearly, so at a minimum, this utilization is impacting a fraction of those at risk. Many at-risk individuals do not consider themselves at risk, and so do not seek care; whereas others are not engaged in healthcare or relationships with providers, so have no context to engage in this method of prevention [7, 8, 15, 16] .
There has been an increase of 
KEY ISSUES IN ADOPTION OF PREEXPOSURE PROPHYLAXIS FOR PROVIDERS

Risk compensation and toxicity
Providers, both specialists and primary care have expressed reservations about offering PrEP. Their concerns have focused on risk compensation, toxicities, and increased costs [22,23 & ,24] . Multiple studies have now documented that there has been no increase in rate of sexually transmitted infections and the use of condoms has been fairly constant during the study period [3
There is an association of greater adherence in men who have higher risk sexual contact, rather than an increase in risky behaviors across the demographic. These concerns about risk compensation mirror the concerns around oral contraceptives, and though there were some early increases in rates of gonorrhea, there has never been a definitive link between the pill and increased rates of sexually transmitted infections (STIs) [26] .
KEY POINTS
PrEP has been demonstrated to be effective in clinical demonstration projects in the USA and over 80% of the patients took enough doses to be protected against HIV.
The uptake of this prevention tool has been slow for the first 2 years and is beginning to increase because of greater provider comfort and patient demand for this approach.
The implementation of PrEP will not likely be the same for all populations at risk. Women and adolescents will likely need different strategies of engagement and follow-up to ensure adequate adherence. AfricanAmericans have not been adequately represented in the demonstration projects in the USA and may need specific strategies to optimally engage this community.
More work is needed to help both providers and patients discuss sexual risk and how to prioritize who is at greatest need for PrEP. There is still ambivalence and some stigmatization regarding asking and using this mode of prevention, and further education is still needed for both patients and providers.
The toxicities associated with Truvada have been mostly short-term side-effects such as nausea (most prominent in the first month), headaches, and weight loss [2,3 && ,7,10] . Longer term side-effects such as decline in renal function and loss of bone density have been seen in longer term use in HIV positive patients, and will be evaluated over time in PrEP [27] [28] [29] These longer term side-effects may be ameliorated as new options for prevention are available, such as cabotegravir (an injectable medicine) [30 & ,31] and tenofovir alafenamide (precursor to tenofovir), which appears to not have much of the overlapping toxicities of Truvada [32, 33 && ].
Costs
The cost of the medications has been a consistent issue of concern for both providers and community members; however, most health plans have covered this on label indication. Individual insurance plans and multiple tiered copays have made PrEP less feasible in cost-constrained settings though Gilead (the manufacturer of Truvada) has expanded their patient assistance program to help with these copays. In states that have not expanded to Medicaid as part of the Affordable Care Act, many have been left out leaving those at highest risk for HIV acquisition with limited availability of PrEP access. Additionally, utilization of assistance programs and navigation through insurance benefits and claims require some healthcare system knowledge, and many individuals will need help with this. The cost -effectiveness of PrEP has been addressed in a review in this series and documented as beneficial in high-incidence populations [34] [35] [36] . However, there is a real issue of direct costs for patients who purchase the medication because of the copays for purchase of the prescriptions as well as the laboratories needed to monitor the safety of Truvada. These copays are only partially covered by patient assistance programs and still may result in monthly costs that vary widely for patients based on their particular insurance coverage. These combined costs of copays for labs and medications could vary from 0 to as high as US $5000 annually. This is a definite barrier to the adoption of PrEP and remains a key challenge to optimal utilization.
Efficacy
The clinical efficacy of PrEP has been well documented in this journal and through numerous pub-
. The number of clients needed to treat in both Ipergay and Proud study was less than 1 in 20 [4, 5] When compared with the number of clients needed to treat with statins to prevent a nonfatal heart attack (one in 39) [37] , this is clearly an important intervention to potentially decrease the rate of new HIV infections with costs benefits if used with the right population and monitored properly.
Delivery models
There is a need to expand the pool of providers to offer PrEP beyond HIV specialists and integrate this approach into primary care [38 && ,39]. Providers are generally aware of the benefits of PrEP, but many would like more training before they begin dispensing medication [40] . Blumenthal and colleagues' [41] recent study found prior PrEP knowledge increased the likelihood of a provider to have prescribed PrEP. In 2013, the total primary care providers in the USA were estimated to be over 280 000 (physicians, nurse practitioners, and physician assistants) [42] . Primary care providers play a key role in keeping their patients healthy and are perfect locations in which to hold conversations on health promotion and disease prevention. Incorporating HIV prevention and discussions on sexual health will reach a larger population at risk for HIV infection that would not come in contact with a sexually transmitted disease (STD) clinic or infectious disease specialist. Increased provider training will be needed to facilitate discussion of the concepts of risk and sexuality with patients [43] . A well known HIV provider stated that 'People are more comfortable having sex, then talking about it'. The conversation between a provider and patient about sex, and the attendant risks of different types of sex, is one seldom had.
A recent study found that MSM who were uncomfortable disclosing their sexuality with their providers were less likely to ever learn or use PrEP. This survey by Krakower and colleagues reported troubling findings: 42% of these men were not comfortable discussing male-to-male sex with their primary care provider, and of the 82% of the men who were comfortable discussing sex many did not feel comfortable discussing PrEP use and approximately three-quarters did not think their provider would be willing to provide PrEP. The group of men who were uncomfortable discussing sex with their provider, were less likely to have discussed anal sex (89 vs. 42% of those who were comfortable) and generally preferred to get PrEP from a provider other than their usual provider (81 vs. 33% of those who were comfortable discussing these issues) [44 && ]. A key factor in the development of PrEP will be access to services. Initial efforts after approval were split between primary care providers and research projects such as the PrEP demo project. This has begun to change as characterized in a recent study by Volk et al. who described the integration of PrEP at the Kaiser Permanente Medical Center in San Francisco, a health maintenance organization. They developed a specialized program with a multidisciplinary team that received 1045 referrals from July 2012 through February 2015, with a marked increase in the rate of referrals in the last year. These referrals generated over 650 individuals with a mean duration of 7.2 months of use (99% MSM). There were no new HIV infections in the cohort on PrEP despite high rates of STIs (50% with any STI after 12 months of use). 74% of the men had no increases in their number of sexual partners and 41% reported decreased condom use [45] .
The delivery model of PrEP is evolving. Integration of these services into primary care settings for individuals at risk has clearly begun as evidenced by data from Boston, Chicago, and San Francisco. However, there is a need to expand prevention services into the STD clinics as well, as this is a location where high-risk behavior has brought one into a clinical environment. PrEP is beginning to integrate into the fabric of public health in various states [46, 47] , and this integration may prove valuable to allow for greater access. A frequent clinical engagement point for many MSM at risk for HIV are STD programs, which many jurisdictions are beginning to use as starting points for PrEP initiation. Through increasing local PrEP awareness at the patient level (via social media or information campaigns) and engaging community stakeholders, STD clinics may represent a logical entry point and referral source for sexual wellness and HIV prevention programs. The challenge will be in continuing the necessary longitudinal care model for PrEP in a setting that has traditionally been focused on episodic care. Local health departments and recent CDC funding support may assist in this transition to longitudinal treatment and monitoring.
The Washington, DC Department of Health is currently developing a PrEP program and other prevention services to be nested within their STD programs to expand outreach for prevention. The evolution of prevention services may stimulate creation of additional specialty PrEP programs as well, such as seen in San Francisco. The development of this clinical model to deliver PrEP will be different in various communities and will be an area for likely future innovation.
However, after the publication of preexposure prophylaxis initiative (iPrEX) in 2010, Krakower reported that as many as one-quarter of providers in some settings continued to be unaware of CDC or FDA guidance on PrEP [48] . Castel reports in a survey of providers two classes of providers, those with more experience and training who felt comfortable providing and those with less experience and training who were reluctant to provide PrEP [49] . There remain serious operational issues, such as which providers will provide the care, and reimbursement.
KEY ISSUES IN ADOPTION OF PREEXPOSURE PROPHYLAXIS FOR COMMUNITY
Recognizing risk
As mentioned previously, the population who could potentially benefit from PrEP is large; however, enabling at-risk populations to recognize their personal risk and translate this into motivation to access PrEP is a key challenge. The community of men and women at risk for contracting HIV infection is quite heterogeneous. The MSM community has a higher risk profile than the heterosexual community as evidenced by the high proportion of new HIV positives who are MSM. Therefore, outreach to populations at greatest risk must engage MSM community and adolescent MSM who represent the age group (15-24 years old) at greatest risk [12] . The key factors are recognizing risk both for the individual as well as the provider and then subsequent engagement to offer PrEP. Men and women at risk for HIV through sexual behavior are frequently unaware about their risk [50, 51] . Kwakka's survey conducted at an STD clinic demonstrated that although 65.4% of the population were open to using PrEP, their estimation of self-risk when compared with the trained outside observer was widely differentiated (9.5% identified self-risk compared with 68.5% by outside observer). Even with an overall negative association between self-risk underestimation and openness to PrEP, receptiveness was high across all races and ethnicities among those who may be clinically eligible for prophylaxis: 69.8% of African-Americans, 74.1% of Hispanics, and 71.7% of Whites who were identified by testers as being at high or moderate risk were receptive [52 & ]. There is a distinction between the global understanding that people have of belonging to an at-risk population and the actual understanding that they as individuals are at risk even when they partake in behaviors that place them at risk.
African-American men, (especially MSM) and women of color are disproportionately impacted by HIV [53, 54] . Ongoing studies such as the HIV Prevention Trials Network study (HPTN 073) 073, (225 Black MSM recruited in DC, Los Angeles, and North Carolina) a demonstration project with a rich model of social support will provide vital information on PrEP uptake and use. African-American men have been underrepresented in previous PrEP studies and it is hoped these current studies and CDC-planned activities will foster broader participation.
The use of PrEP in women is a critical issue as women represent 25% of new HIV infections in the USA [55] . These women have unique risks compared with their men counterparts. Jennings and colleagues' analysis of over 1000 African-American women in HPTN 064 identified many of the unique vulnerabilities that affect women. For example, knowledge of their partner's serostatus, a key component of HIV prevention, is strongly related to financial security and that women with fewer economic resources are less likely to have power in a relationship to negotiate knowledge and protection against HIV [56 & ]. PrEP for these women must combine more than just a pill, but behavioral, economic, and empowerment approaches are likely to be more effective in addressing the multiplicity of vulnerabilities of this population.
Finally, there are few data regarding transgender people, as there has been insufficient clinical experience or participation in clinical trials to really describe the clinical effectiveness. Concerns were raised in the iPrEX Open Label Extension (OLE) trial that drug levels for TDF/FTC were lower as compared to MSM [3 && ]. The rationale for this may simply be related to suboptimal adherence since there is no recognized drug interaction between exogenous hormones and TDF/FTC levels; however, further study is exploring this possible connection.
Stigma around HIV continues even in the realm of new HIV prevention efforts. Opponents of PrEP have made arguments against it based on moral judgments about condom use rather than evidence from clinical trials. The use of a medication to prevent HIV has caused some to be labeled as immoral, promiscuous, and 'Truvada Whores'. The AIDS Healthcare Foundation, which is the largest provider in the USA of HIV services, has been openly critical of this approach, while running provocative advertisements proclaiming the death of condom use as men flock to these pills without any behavioral conscience. This idea of risk compensation has not materialized based on data from numerous trials including iPrEX, PrEP Demo project among others [3 && ,4,5,6 && ]. However, it has touched a sensitive point of how we counsel men and women who continue to have risky sexual behavior that can expose them to HIV.
Consumer engagement
Digital and social media campaigns and discussions may represent unique methods for disseminating information about PrEP and other methods of HIV prevention. Social media may be especially helpful in reaching young adults and adolescents who utilize this frequently and increasingly [57] . Online communication and education may allow for open and frank discussions about sexual risk and methods for prevention without the fear of self-disclosure and stigmatization.
Americans are researching online for health information in addition to visiting provider offices as reflected in 2013, 59% reported looking online for health information in the preceding year according to Pew Research Center's Internet & American Life Project [58] . Providing accurate and timely information about PrEP online can increase engagement with at-risk individuals, empower them to recognize the risk of their own behaviors, and to discuss potential options with their providers as well as host online forums for discussions about PrEP access, availability, side-effects, and personal stories to support sustained use of PrEP.
FUTURE CHALLENGES AND DIRECTIONS
The recent release of six different studies demonstrating the effectiveness and potential of PrEP to impact the epidemic has created a critical momentum for both consumers and providers [2, 3 && ,4,5,6 && ,7]. Recent modeling work by Grant, show what the combined approach of PrEP and treatment as prevention can offer for communities when PrEP uptake increases from a third to 95% amongst those in need, and viral suppression increases from the current 62-90% [14] .
Kelley and colleagues [59] were not as optimistic as Grant, based on their analysis in Atlanta that because of various structural and societal obstacles it would be unlikely to achieve more than 44% coverage for MSM in Atlanta, which could avoid 25% of new infections over a 10-year-period. The estimate of 44% is optimistic, as current data show that only 15% of MSM who would be appropriate are accessing the medicine. Mayer et al. comments on the myriad of reasons contributing to these sobering data. The intersection of social constructs with less health access among African-Americans, compounded in MSM population, stigmatization, and finally the financial issues of inadequate insurance throughout much of the USA impedes efficient and cost-effective rollout of PrEP.
CONCLUSION
We are at a crossroads regarding the provision of PrEP in the USA. There has been enough data to
The preexposure prophylaxis revolution Elion and Coleman satisfy skeptics that this intervention is effective when taken at least four times a week with minimal toxicity, especially considering the age of clients and the intermittent nature of using this approach. The barriers to providing adequate prevention are operational and societal. These obstacles are not simple to overcome and will be a litmus test for our evolving healthcare system that will seek to find the sweet spot between decreasing the incidence of an infectious disease and the cost/benefits associated with the societal commitment to provide this for all appropriate populations. HIV is unique; however, in that it is transmitted through sex, a topic still difficult for both providers and consumers to talk freely about. Locquiao for their expert assistance in helping us to learn about PrEP, and finally all the participants in the studies for helping to educate us.
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